Published on 4 Jun 2023 on Simply Wall St. via Yahoo Finance
Fate Therapeutics, Inc.'s (NASDAQ:FATE) price-to-sales (or "P/S") ratio of 3.8x might make it look like a strong buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 13x and even P/S above 61x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.
See our latest analysis for Fate Therapeutics
ps-multiple-vs-industry